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Abstract. Hormone therapy is a viable technique used to treat endocrine receptor
positive cancers. Using the recently developed theory of cancer networks, we create a
mathematical model describing the growth of an estrogen-receptive cancer governed
by a linear cancer network. We then present hormone therapy as a drug that
blocks the estrogen receptors of different cells in the network. Depending on the
effectiveness of the drug, the model predicts coexistence of healthy and cancerous
cells as well as a cure state. In the case of coexistence, the carrying capacities of
all cancerous cells are reduced by hormone therapy, increasing effectiveness of other
treatments such as surgery.
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1 Introduction
Cancer is an invasive disease of the body that is a result of a mutation or set of mutations in
the healthy cells of an individual. This mutation prevents cells from carrying out apoptosis
or cell death, instead causing them to grow rapidly and eventually form a tumor that, with-
out treatment, kills the host [6, 7]. Many treatments have been developed to fight specific
forms of cancer, yet there is still no cure for cancer.
With the exception of skin cancer, breast cancer is now the most common cancer among
women [6]. Breast cancer starts in the cells of the ducts or lobes of the breast, known
as the epithelial cells, and can invade the surrounding tissue. Breast cancer can occur in
many forms including endocrine receptor positive for estrogen, endocrine receptor positive
for progesterone, HER2 positive, or negative for all three [6]. The most common type of
breast cancer forms when escalated levels of estrogen cause an increase in the rate of cellular
division. The corresponding increase in DNA replication leads to mutations in healthy cells
resulting in endocrine receptor positive breast cancer [1].
Currently, treatment options for breast cancer include radiation therapy, hormone ther-
apy, targeted therapy, chemotherapy, and surgery. Hormone therapy only works for hormone
receptive positive breast cancer and is typically used to help lower the risk of breast cancer
reoccurring after surgery. Hormone therapy can be used in pre- and post-menopausal women
to help in the breast cancer remission stage. One current area of research seeks to determine
whether this form of treatment can help reduce the size of tumors in the breast so that breast
conserving surgery may be performed [6].
There are different forms of hormone therapy. For example, specific drugs can prevent
estrogen from binding to estrogen receptors in the cancerous epithelial cells or prevent the
body from producing estrogen. The drug Tamoxifen has been used for over 30 years as an
adjuvant treatment to lower the risk of breast cancer recurrence, as preventative medication
for women who are at high risk of getting breast cancer, or as a way to slow down endocrine
positive breast cancers that have metastasized. Tamoxifen attaches to estrogen receptors in
endocrine receptor positive cancer to prevent the cells from dividing. Tamoxifen inhibits the
estrogen receptors and induces apoptosis of the cancerous cells [2, 4].
In order to create a mathematical model of hormone therapy, we must select a framework
to describe the onset of cancer and the fundamental interactions between healthy and can-
cerous cells. Recently, Eric Werner has proposed a new paradigm for cancer growth which
suggests that cancer develops as a result of mutations to developmental control networks.
He introduces various types of cancer networks that describe the behavior of cancer stem
cells [7]. These stem cells divide based on instructions from their network to produce tumor
cells. We consider linear cancer networks in which a cancer stem cell can either divide into
itself or differentiate into a terminal tumor cell.
Once we establish a model of a linear cancer network, we extend the model to include
the effects of estrogen availability and hormone therapy in the growth or cure of estrogen
receptor positive breast cancer. The model establishes specific conditions on the effectiveness
of a receptor-blocking drug on cancer stem cells and healthy epithelial cells that determine
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whether the treatment fails, cures the cancer completely, or reduces final tumor size. In the
latter case, reduction of the tumor size may allow for breast-conserving surgery.
In Section 2 we describe relevant mathematical models of breast cancer and establish a
framework for a mathematical model of cancer stem cells, cancer tumor cells, and healthy
epithelial cells in the breast. In Section 3 we present an original system of differential equa-
tions as a model for breast cancer dynamics and treatment via hormone therapy, which we
simulate in Section 4 by choosing specific parameter values and producing graphs that show
the behavior of our model both with and without treatment. In Section 5 we explore long-
term behavior of the model with a local stability analysis and address the robustness of the
model with a sensitivity analysis. We then in Section 6 discuss the biological significance
of each equilibrium point and suggest possible insights into cancer recurrence and viability
of neoadjuvant treatment. Finally, in Section 7 we provide some concluding remarks and
outline potential future directions for research.
2 Background of Models
Many current mathematical models of cancer utilize systems of first-order differential equa-
tions to represent the populations of cancerous cells and healthy cells. For instance, in [3],
Mufudza, Sorofa, and Chiyaka consider a Lotka-Volterra type system of four ordinary dif-
ferential equations to describe the interactions among healthy, tumor, and immune cells, as
well as excess estrogen levels in breast cancer. Shimada and Aihara [5] explore androgen
suppression therapy by presenting a system of three ODEs that monitor androgen-dependent
and independent cells in prostate cancer. Moreover, models that incorporate cancer stem
cells have the potential to address open questions in cancer research, such as recurrence
or spontaneous remission. Properly targeting cancer stem cells may lead to new treatment
options that could eradicate tumors and offer longer periods of remission.
Our approach in creating a mathematical model of the interactions between cancer stem
cells and cancer tumor cells will be to use linear cancer networks. As described by Werner
[7], a linear cancer network occurs when a cancer stem cell (A) divides and produces another
cancer stem cell and a cancer tumor cell (B). This means that the cancer stem cells will
stay constant but the cancer tumor cells will be produced linearly by the cancer stem cells.
We use Werner’s idea as a framework to create a set of two differential equations to
model the growth of cancer stem cells (A) and cancer tumor cells (B). To anticipate the
effect of hormone therapy both on cancerous and healthy cells, we include a third differential
equation that describes the growth rate of healthy cells (H) within the breast tissue.


























The healthy cells of the model only refer to the epithelial cells of the breast that are near
the site of the tumor, and we assume that these cells grow logistically at a rate of q. We
also assume that cancer stem cells grow logistically at a rate of k. M1, M2, and M3 refer
to the carrying capacities of stem, tumor, and healthy cells, respectively. The fraction A
M1
represents the proportion of stem cell divisions that differentiate into tumor cells. While k
accounts for the net growth rate of A cells, it only describes the birth rate of B cells (recall
that we follow Eric Werners assumption that B cells are terminal and do not divide on their
own [7]); therefore, we include a natural death rate n of B cells.
3 Breast Cancer Model
The above models [3, 5] support the choice to represent the dynamics of estrogen (relative
to a natural equilibrium level) explicitly with an ODE. In order to include linear cancer
networks, our model also separates cancerous cells into two categories: cancer stem cells and
tumor cells. However, we assume that Lotka-Volterra competition between cell populations
is negligible and that all cell types are estrogen-dependent. Using Eric Werner’s framework,



























































Since the model shows the growth of cells that are estrogen dependent, we had to consider
how estrogen would effect how the cells grow. The term E
E0
accounts for how estrogen helps
the cells grow. E0 serves as the carrying capacity for E. When E < E0, then the rate that
cells are dividing due to estrogen are slower than when E > E0. When E = E0, then the
cells are dividing normally. The amount of available estrogen has logistic growth (with rate
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A = Number of cancer stem cells
B = Number of tumor cells
H = Number of healthy cells
E = Amount of estrogen available to bind to estrogen receptors in the cells
k = Normal rate of division for A cells
E0 = Normal amount of estrogen needed for all cells to divide normally
M1,2 = Carrying capacities of cancer stem cells and tumor cells
d1,2 = Rate at which A and B cells are dying from lack of estrogen
n = Death rate of B
q = Normal growth rate of healthy cells
M3 = Carrying capacity of healthy cells
d3 = Rate that healthy cells are dying from lack of estrogen
r = Logistic growth rate of binding estrogen
s = Effectiveness of the Tamoxifen at blocking estrogen receptors
D = Dose of Tamoxifen
r) because as the cells use estrogen, more estrogen is being replenished by natural functions.
In pre-menopausal women, the ovaries produce estrogen, and in post menopausal women





found in the other equations
describes the proportion of available estrogen that is unable to bind to receptors. As E
decreases, this proportion grows larger and has an increasingly negative effect on cellular
growth. The dosage (D) of Tamoxifen we assume constant because it is taken daily [6], and
s describes the effectiveness of Tamoxifen at reducing available estrogen.
4 Results
With the model in place we now perform numerical simulations using Mathematica 9. We first
simulate the model without treatment to visualize normal interactions between cancerous
cells, healthy cells, and available estrogen.
4.1 Without Treatment
We let D = 0 to represent a no-treatment case. From a simple stability analysis we conclude
that the only stable equilibrium point for this model is when the cells and estrogen co-exist.
The graph in Figure 1 shows the dynamics of the model.
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Figure 1: Breast cancer growth model before treatment
4.2 With Treatment
We then wanted to show the effects of introducing the drug Tamoxifen. Using the following
set of parameters found in Table 1 we produced four graphs (see Figures 2, 3, 4, and 5)
showing different outcomes of the model.












Figure 2: All cells are dead and only estrogen is available
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Figure 3: The cure state where all cancer cells are dead and healthy cells survive












Figure 4: All cells and available estrogen coexist












Figure 5: All healthy cells die and cancer cells live
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Parameter Graph 1 Graph 2 Graph 3 Graph 4
k .65 .65 .65 .65
E0 100 100 100 100
M1 20 20 20 20
M2 40 40 40 40
d1 .55 .55 .55 .10
d2 .65 .65 .65 .20
n .25 .25 .25 .25
q .75 .75 .75 .75
M3 60 60 60 60
d3 .1 .1 .1 .7
r .65 .65 .65 .65
s .60 .45 .15 .45
D 1 1 1 1
Table 1: Parameters for breast cancer growth model
5 Analysis of Model
To gain insight on how changing parameters in the model lead to each of the four distinct
behaviors in Figures 2, 3, 4, 5, we place our system in dimensionless form and conduct
stability and sensitivity analyses.
5.1 Dimensionless Form
The dimensionless form reduces the number of parameters in the model so that the analysis
is easier to conduct.
x′ = wx(1− x)− δ1(1− w)x (1)
y′ = µwx2(1− y)− ηy − δ2(1− w)y (2)
z′ = γwz(1− z)− δ3(1− w)z (3)
w′ = ρ(1− w)w − σw (4)
where
5.2 Equilibrium Points
We set the differential equations 1, 2, 3, and 4 simultaneously equal to 0 in order to find the
equilibrium points of our model. Let
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x = AM1 ,
y = BM2 ,
z = HM3 ,




k ,i = 1, 2, 3
η = nk ,
γ = qk ,
ρ = rk ,
σ = sDk .
x̄ =
ρ− σ − δ1σ
ρ− σ
ȳ =
µ(ρ− σ − δ1σ)2
µ(ρ− σ − δ1σ)2 + (ρ− σ)(ηρ+ δ2σ)
z̄ =





The dimensionless model gave 5 equilibrium points:
P1 = (0, 0, 0, 0)
P2 = (0, 0, 0, w̄)
P3 = (x̄, ȳ, 0, w̄)
P4 = (0, 0, z̄, w̄)
P5 = (x̄, ȳ, z̄, w̄)
We can then analyze the stability of each equilibrium point by plugging each one into
the resulting Jacobian matrix, but first we will discuss the positivity of these points.
5.3 Positivity of Equilibrium Points
In order to determine when each of our populations can approach a non-negative steady
state, we must establish conditions on our parameters to ensure that each point is located
in
R4+ = {(x, y, z, w) : x, y, z, w ≥ 0}.
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Clearly, P1 ∈ R4+. To guarantee that w̄ > 0 in the remaining four equilibrium points, we
require that
ρ > σ (5)
and we make this assumption for the remainder of the paper. Consequently, P2 ∈ R4+. Next,










Thus, assuming (7) holds, P4 ∈ R4+. From (5) , (6) we conclude that ȳ > 0. Therefore
P3,P5 ∈ R4+.
5.4 Stability Analysis of Dimensionless Model
After establishing conditions that ensure the positivity of the equilibrium points, we find the
Jacobian matrix of the dimensionless model. The Jacobian matrix will be used to analyze
the local stability of each equilibrium point.
w − 2xw − δ1 + δ1w 0 0 x− x2 + δ1x
2µwx− 2µwxy −µwx2 − η − δ2 + δ2w 0 µx2 − µx2y + δ2y
0 0 γw − 2γwz − δ3 + δ3w γz − γz2 + δ3z
0 0 0 ρ− 2ρw − σ

The four eigenvalues of the Jacobian matrix evaluated at P1 follow:
λ1 = −δ1
λ2 = −δ3
λ3 = −δ2 − η
λ4 = ρ− σ

Note λ4. Since we concluded that ρ has to be greater than σ the origin, or equilibrium
point P1, will always be unstable. For the remaining four equilibrium points, inequalities (6,
7) lead to four cases where each equilibrium point becomes stable based on sign changes in
the eigenvalues.






























For case 1, P2 is the only point stable because when (6),(7) are reversed, then all other
cases have a positive eigenvalue. All other cases follow a similar argument as the first.
Figure 6: This graph shows the positivity and stability of our model.
Since ρ and σ play an important role in the long term behavior of the model, we next
perform a sensitivity analysis to explore how other parameters affect the model.
5.5 Sensitivity
For the sensitivity analysis, baseline parameters were chosen to place our model in case 3
of coexistence. We will be measuring the dimensionless fraction (y) of remaining tumor
cells after an extended period of time. These parameters (found below in Table 2) gave
a remaining fraction of the tumor cells of .221253. The parameters ρ and σ will be set to
maintain coexistence. We will also fix the parameters γ and δ3 that have no effect on the
fraction of remaining tumor cells we are observing. The remaining values will be changed by
a certain percentage from their baseline, and the change in the remaining fraction of tumor
cells will be recorded.










Table 2: Fixed parameters for sensitivity analysis











































The analysis of the model produced five equilibrium points. All the points have biological
meaning in relation to explaining the cancer growth dynamics. P1 represents the situation
where there are no cells (cancer, tumor, or healthy) and no binding estrogen. P2 represents
where all cells are dead and there is only estrogen available, while P3 shows a case where the
cancer cells (stem and tumor) are existing with available estrogen but all the healthy cells
are dead. P3 could describe the situation where cancer has killed the host. P4 represents a
cure state where the cancer has gone into permanent remission. This may be possible if the
right drug/treatment is administered and is 100% effective but typically this does not happen
with hormone therapy. This is because over time the cancer cells which are dependent on
estrogen slowly develop into independent cells that grow regardless of estrogen binding to
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receptors [5]. P5 represents the coexisting state and in this state breast conserving surgery
can be done.
Our stability analysis shows that two key inequalities determine the long term behavior
of the model. It is interesting to reformulate these inequalities in terms of σ to reveal how
the effectiveness of the drug impacts this behavior. For example, in the case where P5 is







Notice that as δ1 increases (i.e. stem cells are more negatively affected by blocked estrogen
receptors), it becomes more likely that σ will instead exceed the threshold stated in the
first inequality and transfer stability to the cure state P4. A corresponding risk occurs when
increasing δ3; a poorly targeted drug can cause significant damage to healthy cells. Perhaps
the most interesting feature of these inequalities is the noticeable lack of δ2. No matter
how effective the drug is at blocking estrogen receptors of tumor cells, unless δ1 is large, the
cancer will not be cured. However, larger values of δ2 do succeed in decreasing the steady-
state population of tumor cells, ȳ.
One possible consequence is that making ȳ sufficiently small may create the illusion
of achieving remission. In such a case, though, recurrence of the cancer would inevitably
follow if δ1 (or σ) was not large enough to guarantee a stable cure state. This scenario may
indeed be quite likely if the cells of a particular tumor contain significantly more estrogen
receptors than the corresponding cancer stem cells. On the other hand, a diminished size of
ȳ may make other treatment options such as surgery more plausible; our model thus predicts
estrogen therapy can be useful as an option for neoadjuvant treatment.
7 Conclusion
Using a linear cancer network, we have produced a model which illustrates how hormone
therapy can be used as a viable option for curing or reducing tumor sizes of estrogen re-
ceptor positive breast cancer. Future work will consist of finding more biologically realistic
parameters, exploring other types of cancer networks, and incorporating interactions with
immune cells or estrogen-independent cells.
Note: All graphs appearing in this paper were produced using Mathematica 9.
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